Latest Breaking News On - Aravind asokan - Page 5 : vimarsana.com

RESEARCH TRIANGLE PARK –StrideBio, an emerging startup focusing on gene therapies, is gearing up for more growth after closing on a big $81.5 million round of venture capital. Backed by Hatteras Venture Partners in Durham, StrideBio announced the new, second round of cash early Tuesday. The round was oversubscribed, the company says. In 2018, StrideBio raised nearly $16 million in an oversubscribed first round of funding. The new funding comes after StrideBio struck a $48 million licensing deal with rare disease drugmaker Sarepta Therapeutics in 2019. Sapan Shah, a 20-year life science industry veteran, was named StrideBio’s CEO that same year. “We are very pleased to receive such tremendous support from these top-tier healthcare investors and appreciate the confidence they have placed in our entire team,”Shah said of the new funding. “With this additional funding secured we will be able to translate next generation gene therapies enabled by our lead engineered capsid

Al iskandariyahMavis agbandje mckennaAravind asokanKaren hongSapan shahShaanc gandhiUniversity of floridaNovo holdingsHatteras venture partnersSarepta therapeuticsCrispr therapeuticsChapel hillOctagon capitalCaas capitalTakeda venturesAlexandria venture